IgAN vs Other Glomerular Diseases

Author(s):

Jonathan Barratt, PhD, FRCP,Anuja Java, MD

Key Takeaways

IgA nephropathy involves aberrant glycosylation of IgA1, leading to immune complex deposition in the glomerular mesangium.
This condition is distinct from other glomerular diseases due to its specific association with IgA1 and mucosal immune responses.
Genetic predispositions and unique immune mechanisms differentiate IgA nephropathy from other glomerulopathies with varied immune triggers.

Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.

IgAN vs Other Glomerular Diseases

Key Takeaways

EP: 1.Overview of IgAN and Its Common Symptoms

EP: 2.IgAN Progression

EP: 3.IgAN vs Other Glomerular Diseases

EP: 4.Biomarkers for IgAN

EP: 5.Genetic Screening for IgAN

EP: 6.Impact of IgAN on Quality of Life

EP: 7.Misdiagnosis and Barriers to Early Detection of IgAN

EP: 8.Differential Diagnoses of IgAN

EP: 9.Significance of Proteinuria for Potential IgAN

EP: 10.Proteinuria Variability and IgAN Diagnosis

EP: 11.Biomarkers and Improving IgAN Diagnostic Accuracy

EP: 12.Primary Treatment Goals for Patients With IgAN

EP: 13.Proteinuria Reduction in Long-Term Kidney Damage Prevention

EP: 14.Symptoms Management and Targeting the Root Cause of IgAN

EP: 15.Unmet Needs in Current IgAN Treatment

EP: 16.Prospective Improvements of Existing IgAN Therapies

EP: 17.Safety of IgAN Treatments

EP: 18.The Promise of Emerging IgAN Therapies

EP: 19.Emerging Therapies: a look at the current data: ALIGN

EP: 20.Emerging Therapies: a look at the current data: APPLAUSE

EP: 21.Emerging Therapies: a look at the current data: PROTECT study

EP: 22.Emerging Therapies: a look at the current data: NefIgArd study